A study confirms the effectiveness of the combination of AstraZeneca and Sputnik V vaccines against the coronavirus – Telam

Preliminary results of a study on the combined use of the AstraZeneca vaccine and the first dose of Sputnik V has shown efficacy against coronavirus infection and absence of side effects in immune individuals, reported the Russian Direct Investment Fund (RDIF).

“Interim analysis of the data shows high safety indicators for combined drug use, with the absence of side effects as well as cases of coronavirus infection after vaccination,” says a RDIF statement reported today. hui by the Sputnik news agency.

The text states that “in August 2021, RDIF and its partners will publish the first data on the immunogenicity of the combined use of the AstraZeneca vaccine and the first component of the Sputnik V vaccine in Azerbaijan”.

Safety and immunogenicity studies, that is, the drug’s ability to trigger an immune response, began in Azerbaijan last February, where 50 people were vaccinated although the admission of volunteers continues.

RDIF pointed out that the clinical study of the vaccine combination is carried out as part of a global program which also covers the United Arab Emirates, where volunteers have already been immunized, as well as Russia and Belarus, countries in which it has been cleared by local regulators but trials have not yet started.

Studies began in Azerbaijan last February, where 50 people were vaccinated although admission of volunteers continues“

“Under conditions of the emergence of new variants of the coronavirus, the cooperation of vaccine producers and the combination of different vaccines play a crucial role in the successful fight against the pandemic,” said RDIF boss Kiril Dmtriev, quoted in the notice.

He also explained that “based on the high efficiency of the heterogeneous stimulus or vaccine cocktail, RDIF was the first in the world to make a proposal for cooperation with other producers of anticovid vaccines.”

“The first such collaboration was joint clinical trials with the company AstraZeneca,” he added.

Last December, RDIF and the Nikoli Gamaleya Center for Epidemiology and Microbiology, developer of the Sputnik V vaccine, and the R-Farm group of companies signed a cooperation protocol with AstraZeneca for the development of vaccines against the coronavirus.

R-Farm Managing Director Vasili Igntiev, for his part, stressed the importance that the first test results were obtained when the Delta spread., originally from India and is characterized by being more transmissible.

Meanwhile, AstraZeneca’s Managing Director in Russia and Eurasia, Irina Panarina, said the vaccine cocktail “is one of the most encouraging vaccination programs.”